Self-Collected HPV Testing Now Accepted for Cervical Cancer Screening
Quick Facts
What Changed in the Screening Guidelines?
The acceptance of self-collection for cervical cancer screening represents a paradigm shift. For decades, screening has required a clinician-performed pelvic examination to collect cervical cells, either for Pap cytology (the traditional "Pap smear") or for HPV DNA testing. While this approach is effective, it creates significant barriers for many patients: discomfort, embarrassment, need for a clinical appointment, lack of access to healthcare providers, and cultural or personal objections to pelvic examinations.
The American Cancer Society's 2020 guideline update established three acceptable screening strategies for individuals aged 25-65:
- Primary HPV testing every 5 years (preferred) — with self-collection now recognized as a valid option following FDA approval
- Co-testing (HPV plus Pap cytology) every 5 years — requires clinician collection
- Pap cytology alone every 3 years — requires clinician collection
The inclusion of self-collection as a screening option is supported by a large body of evidence. A major meta-analysis published in the BMJ, analyzing data from multiple studies across several countries, found that self-collected vaginal samples tested with validated PCR-based HPV assays had comparable sensitivity to clinician-collected cervical samples, in the range of approximately 85-95% for detecting cervical precancer (CIN2+). This evidence base continues to grow as more countries adopt self-collection programs.
How Does Self-Collection Work?
The self-collection process is straightforward and designed to be as simple as possible. The individual receives a kit containing a collection device (typically a small flocked swab or brush), a transport tube with preservative solution, clear illustrated instructions, and a prepaid return envelope or instructions for returning the sample to a laboratory.
To collect the sample, the individual inserts the swab approximately 5-7 centimeters into the vagina, rotates it gently for 20-30 seconds to collect cells, removes the swab, and places it into the transport tube. The entire process takes about one minute and can be performed at home, in a bathroom, or in any private setting. No speculum, stirrups, or clinical examination is required.
The sample is then tested in a laboratory using a PCR-based HPV DNA assay, which detects the genetic material of high-risk HPV types (particularly types 16, 18, 31, 33, 45, 52, and 58, which together account for over 90% of HPV-related cervical cancers). Results are typically available within one to two weeks.
It is important to understand that a negative HPV self-test is highly reassuring, with a very high negative predictive value. However, a positive HPV result does not mean cancer is present. Most HPV infections clear spontaneously within one to two years. A positive result triggers follow-up with a healthcare provider for a clinical examination, which may include Pap cytology, colposcopy, or both, to determine whether abnormal cell changes are present.
Who Benefits Most from Self-Collection?
In the United States, approximately 14 million people with a cervix are estimated to be overdue for cervical cancer screening. Screening participation has remained below the Healthy People 2030 target of 84.3%, with significant disparities affecting certain populations. Self-collection has the potential to reach many of these underscreened individuals.
Research consistently shows that the primary reasons people avoid cervical screening include discomfort or pain during pelvic examinations, embarrassment and anxiety about the procedure, difficulty scheduling and attending clinical appointments, lack of health insurance or a regular healthcare provider, cultural or religious concerns about pelvic examinations, and history of sexual trauma that makes examinations distressing.
Studies examining the acceptability of self-collection have found that the vast majority of participants found it easy to perform, and most preferred self-collection to clinician collection. Research also suggests that previously underscreened individuals are significantly more likely to participate in screening when self-collection is available. Randomized trials in countries where self-collection has been implemented — including the Netherlands, Australia, and Denmark — have shown meaningful increases in screening participation, with some programs reporting participation gains of 15-30%.
Frequently Asked Questions
Self-collected HPV testing allows you to collect your own vaginal sample using a simple swab, without needing a pelvic exam. The sample is sent to a laboratory for HPV DNA testing. Research shows that when validated PCR-based assays are used, self-collected samples have sensitivity comparable to clinician-collected samples for detecting high-risk HPV.
Self-collected HPV testing using PCR-based assays has shown comparable sensitivity for detecting high-risk HPV and cervical precancer. However, self-collection is used for HPV DNA testing specifically, not for Pap cytology. If your HPV test is positive, you will need a follow-up visit with a healthcare provider for further evaluation including possible colposcopy.
The ACS recommends cervical screening for individuals with a cervix aged 25-65. The preferred approach is primary HPV testing every 5 years. Screening may be discontinued after age 65 with adequate prior negative results, or after total hysterectomy for non-cancer reasons. Talk to your provider about your personal screening schedule.
Following the FDA's 2024 approval of the first HPV test for self-collection, these tests are becoming available through healthcare providers and select pharmacies in the US. Several countries including the Netherlands and Australia have already integrated self-collection into national screening programs. Check with your healthcare provider about availability and insurance coverage in your area.
References
- Fontham ETH, Wolf AMD, Church TR, et al. "Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society." CA Cancer J Clin. 2020;70(5):321-346.
- Arbyn M, et al. "Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses." BMJ. 2018;363:k4823.
- U.S. Food and Drug Administration. "FDA Approves First Over-the-Counter At-Home HPV Test." FDA.gov. March 2024.
- World Health Organization. "Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem." WHO.int. 2020.
- Polman NJ, et al. "Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial (IMPROVE)." Lancet Oncol. 2019;20(2):229-238.
- Sung H, et al. "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries." CA Cancer J Clin. 2021;71(3):209-249.
- Walboomers JM, et al. "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide." J Pathol. 1999;189(1):12-19.